Can you review the mechanism of action of IL-6 inhibitors in RA, and what we have learned from trials evaluating the safety and efficacy of sarilumab, tocilizumab, and other drugs in this class?

Can you review the mechanism of action of IL-6 inhibitors in RA, and what we have learned from trials evaluating the safety and efficacy of sarilumab, tocilizumab, and other drugs in this class?

Can you provide an overview of the mechanism of action of IL-6 inhibitors in RA, rationale for their use, and what we have learned from landmark trials evaluating the safety and efficacy of sarilumab, tocilizumab, and other drugs in this class?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Roy Fleischmann, MD

Roy Fleischmann, MD

Clinical Professor of Medicine University of Texas Southwestern Medical Center at Dallas Co-Director, Division of Rheumatology Texas Health Presbyterian Medical Center and Co-Medical Director Metroplex Clinical Research Center